About us
Pipeline
Target Markets
Our Technologies
Partnering
News, Media & Events
Investors
Careers
Contact

Home
News, Media & Events
Media Coverage
Destiny Pharma CSO discusses breakthrough treatment for C. difficile infection

Destiny Pharma CSO discusses breakthrough treatment for C. difficile infection

Tel: +44(0) 1273 704440

Email us

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB UK

About us
Pipeline
Target Markets
Our Technologies
Partnering
News, Media & Events
Investors
Careers
Contact

Registered Company No. 3167025

Terms of Use
Privacy Statement

About us
Pipeline
Target Markets
Our Technologies
Partnering
News, Media & Events
Investors
Careers
Contact